Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganciclovir-based antiviral prevention strategies after renal transplantation
ChiCTR-PRC-08000237Phase 4Completed
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ganciclovir in cytomegalovirus disease (CMV) (2 arms), sponsored by Sun Yat-sen University. Primary endpoints: Sensitivity and specificity of different diagnostic indicators, Safety of each prevention strategy and 2 more. Started Jan 2008; status: completed.
02
Drugs
ganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on ChiCTR-PRC-08000237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-PRC-08000237.